title: [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD].
abstract: OBJECTIVE
  The objective was to evaluate the safety and efficacy of a switch in medication to a single daily dose of OROS-Methylphenidate (OROS-MPH, Concerta) in clinically stable children and adolescents with ADHD.
  
  
  METHODS
  A prospective, multi-centre open-label study was carried out for a period of three weeks in 213 patients aged 6-16 years with ADHD who had previously been treated with IR-MPH. Their medication was switched to a single daily dose of OROS-MPH. Primary endpoints were changes in the IOWA Conners Inattention/Overactivity Subscale and the global assessment of efficacy as rated by parents and teachers. The safety of the medication was evaluated by means of recording adverse events. The development of weight, sleep quality, and appetite were also observed.
  
  
  RESULTS
  Switching the medication from IR-MPH to OROS-MPH resulted in a significant positive effect as evidenced by caregivers' ratings of core symptoms. Corresponding ratings by teachers revealed no significant difference from baseline values. The global efficacy was rated by teachers as "good" or "excellent" for 55% of the cases, by caregivers for 79% thereof, and by investigators in 77% of the cases, respectively. The study medication was well tolerated. The most frequent adverse events were headache (8.9%) and rhinopharyngitis (7.0%). No unexpected adverse events occurred.
  
  
  CONCLUSIONS
  Changing patients' medication from IR-MPH to a single daily dose of OROS-MPH resulted in a significant improvement of ADHD symptoms as rated by parents. In a school setting, the efficacy of OROS-MPH was comparable to that of IR-MPH.
authors.affiliation: Praxis für Psychosomatische Medizin und Psychotherapie, Köln.
authors.forename: Steffen
authors.initials: S
authors.lastname: Heger
authors.forename: Götz-Erik
authors.initials: GE
authors.lastname: Trott
authors.forename: Michael
authors.initials: M
authors.lastname: Meusers
authors.forename: Eberhard
authors.initials: E
authors.lastname: Schulz
authors.forename: Aribert
authors.initials: A
authors.lastname: Rothenberger
authors.forename: Klaus
authors.initials: K
authors.lastname: Rettig
authors.forename: Rossella
authors.initials: R
authors.lastname: Medori
authors.forename: Andreas
authors.initials: A
authors.lastname: Schreiner
authors.forename: Helmut
authors.initials: H
authors.lastname: Remschmidt
mesh_terms: D000293:Adolescent; D001288:Attention / Q000187:drug effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage* / Q000009:adverse effects; D009043:Motor Activity / Q000187:drug effects; D010552:Personality Assessment; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D008774:Methylphenidate